Acasti Pharma Company Profile (NASDAQ:ACST)

About Acasti Pharma (NASDAQ:ACST)

Acasti Pharma logoAcasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG). The Company's drug candidate is CaPre, an OM3 phospholipid, which is being developed for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL) (severe hypertriglyceridemia or severe HTG).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACST
  • CUSIP: N/A
  • Web:
  • Market Cap: $18.83 million
  • Outstanding Shares: 14,712,000
Average Prices:
  • 50 Day Moving Avg: $1.30
  • 200 Day Moving Avg: $1.29
  • 52 Week Range: $1.11 - $3.09
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.17 per share
  • Price / Book: 1.18
  • EBIDTA: ($6,190,000.00)
  • Net Margins: -35,290.48%
  • Return on Equity: -47.38%
  • Return on Assets: -43.03%
  • Debt-to-Equity Ratio: 0.06%
  • Current Ratio: 4.55%
  • Quick Ratio: 4.55%
  • Average Volume: 23,976 shs.
  • Beta: 1.22
  • Short Ratio: 4.2
Frequently Asked Questions for Acasti Pharma (NASDAQ:ACST)

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

How were Acasti Pharma's earnings last quarter?

Acasti Pharma, Inc. (NASDAQ:ACST) posted its earnings results on Tuesday, January, 15th. The company reported ($0.02) EPS for the quarter. Acasti Pharma had a negative return on equity of 47.38% and a negative net margin of 35,290.48%. View Acasti Pharma's Earnings History.

Who are some of Acasti Pharma's key competitors?

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the folowing people:

  • Roderick Noel Carter, Executive Chairman of the Board
  • Janelle D'Alvise, President, Chief Executive Officer
  • Linda O'Keefe, Chief Financial Officer
  • Pierre Lemieux Ph.D., Chief Operating Officer
  • Laurent Harvey, Vice President- Clinical and Non-Clinical Affairs
  • Jean-Daniel Belanger, Secretary, Director- Corporate Affairs
  • Valier Boivin, Independent Director
  • Jean-Claude Debard, Independent Director
  • Ronald Denis, Independent Director
  • Pierre Fitzgibbon, Independent Director

How do I buy Acasti Pharma stock?

Shares of Acasti Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of Acasti Pharma stock can currently be purchased for approximately $1.38.

MarketBeat Community Rating for Acasti Pharma (NASDAQ ACST)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  12
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acasti Pharma (NASDAQ:ACST) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Acasti Pharma (NASDAQ:ACST)
No equities research coverage for this company has been tracked by


Earnings History for Acasti Pharma (NASDAQ:ACST)
Earnings by Quarter for Acasti Pharma (NASDAQ:ACST)
Earnings History by Quarter for Acasti Pharma (NASDAQ ACST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/15/2013Q313($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acasti Pharma (NASDAQ:ACST)

No earnings estimates for this company have been tracked by


Dividend History for Acasti Pharma (NASDAQ:ACST)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Acasti Pharma (NASDAQ:ACST)
No insider trades for this company have been tracked by


Headline Trends for Acasti Pharma (NASDAQ:ACST)
Latest Headlines for Acasti Pharma (NASDAQ:ACST)
DateHeadline logoAcasti Pharma Grants Stock Options - June 14 at 3:17 PM logoAcasti Pharma To Present at Upcoming International Industry Conferences - June 12 at 3:43 PM logoAcasti Pharma and CordenPharma Announce Large Scale Production of CaPre® with New Continuous Manufacturing Process - May 31 at 11:15 AM logoAcasti Pharma (ACST) Given Daily News Sentiment Score of 0.12 - April 30 at 11:17 AM logoAcasti Pharma (ACST) Announces Additional Composition & Use Patents in Taiwan and Australia - April 24 at 11:12 AM logoAcasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable Market Expansion Opportunities - April 24 at 11:12 AM logoAcasti Pharma (ACST) Given Media Sentiment Rating of 0.35 - April 20 at 7:35 AM logoAcasti Pharma (ACST) Earns Daily Media Impact Rating of 0.10 - April 15 at 8:44 AM logoAcasti Pharma Provides Update On CaPre Phase 3 Development Program - March 30 at 3:32 PM logoAcasti Pharma Grants Incentive Stock and Options - February 24 at 3:17 PM logoAcasti Pharma (ACST) Reports Proposed Private Placement of Conv. Debentures, Amended Offering of Units - February 2 at 8:21 PM logoAcasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed Offering of Units - February 2 at 3:18 PM logoBiotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma - January 25 at 3:23 PM logoAcasti Pharma Inc. (ACST) Is Spiking Higher In Early Trade - December 23 at 8:25 PM logo8:01 am Acasti Pharma announces that Linda O'Keefe has been named CFO - November 30 at 10:22 AM logoAcasti Pharma (ACST) Names New CFO - November 29 at 3:46 PM logoAcasti Pharma Share Gains Massive in Percentage Terms, Tiny in Dollars - September 14 at 8:34 PM logoAcasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data - September 14 at 9:49 AM logoAcasti Announces Grant of Stock Options - May 30 at 8:00 AM logoJan D'Alvise Appointed President & CEO of Acasti Pharma - May 12 at 8:08 AM logoAcasti Pharma Inc. (ACST) - January 27 at 11:09 AM logo5:10 pm Acasti Pharma reports Q3 net loss of ($2.191 mln) vs $3.012 mln last year - January 12 at 5:10 PM logoACASTI PHARMA INC. Financials - December 8 at 1:12 PM logoAcasti Announces Second Quarter Results - October 14 at 5:10 PM logoAcasti Pharma Gains Ahead Of Expected Phase II Results - February 26 at 2:24 PM



Acasti Pharma (ACST) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff